The Neurotech Investing and Partnering Conference 2012

Boston, MA
Monday, May 21, 2012

Click here for: The Neurotech Investing & Partnering Conference 2013 
Advances in Drugs, Devices and Diagnostics for the Brain and Nervous System
May 23-24, 2013 St. Regis San Francisco

Agenda Neurotech 2012

Location: Intercontinental Hotel, Boston MA, Rose Kennedy Ballroom

  Monday May 21, 2012
 7:30 Breakfast and Registration
 8:30 Welcome: The Global Neurotech Industry 2012
  NeuroInsights provides an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics. 

Casey Lynch, Managing Director, NeuroInsights
 8:45 Investing in Neurotech Panel
  A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Bruce Leuchter, Partner & Managing Director, CP Health Ventures, Director of Neuropsychiatry, Weill Cornell Medical College

Jim Broderick, Partner, Morganthaler Ventures

Jens Eckstein, President, SR One

Eric Elenko, Partner,
Puretech Ventures

Rajeev Shah, Partner,
RA Capital Management

Nicole Walker, Director, Abbott Ventures
Networking and Refreshment Break
10:15  Alzheimer's and Cognitive Disorders
  As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?

Session Chair: Stephen Knight, Managing Partner, Fidelity Bioscience

Sharon Letchworth, Therapeutic Area Leader,

Rick Jack, CEO, Madera Biosciences

Daniel Chain, CEO, Intellect Neuroscience

Daniel O'Connell, CEO, Functional Neuromodulation, Inc.

K.C. Fadem, CEO, Neuronetrix


Neurodevelopmental disorders: Autism and Fragile X
  While extremely challenging, more companies are tackling devastating developmental disorders.  What are the most promising approaches?  What are the opportunities, challenges and risks to diagnosing and treating children and infants with brain disorders?

Session Chair: Manuel Lopez Figueroa, Vice President, Bay City Capital

Robert Ring, Vice President of Translational Research, Autism Speaks

Shafique Virani, Global Head, CNS Business Development and Licensing, F. Hoffman La Roche 

Randall Carpenter, CEO, Seaside Therapeutics

Jan D'Alvise, President and CEO, Pediatric Bioscience

Lunch Keynote

"New Frontiers in Clinical Neuroscience"

Dr. Steven Hyman 
Director of the

Stanley Center for Psychiatric Research, 

Broad Institute at Harvard and MIT
2:00 Internal and External Research & Development
  What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations?

Moderator: Liam Ratcliffe, Partner, New Leaf Venture Partners

Cherise Kent, Director of Business Development,

 Shire Pharmaceuticals

Jit Patel, 

BD Director and VC Liaison, CNS & Pain, AstraZeneca

Sherrie Perkins, VP Marketing and New Business Development, Cyberonics

Guy Seabrook, Sr. Director, Neuroscience External Innovation, Janssen Pharmaceutical 
Networking and Refreshment Break
3:30 Movement Disorders: Parkinson's, Huntington's and ALS
  Exciting developments are in the pipeline for slowing progression of some of the most vexing neurological conditions like Parkinson's ALS and Huntington's.  What is the latest science behind new targets for these disorders? What new drugs and devices are on the horizon?

Session Chair: Todd Sherer,
CEO, Michael J. Fox Foundation

Bharatt Chowrira, President and CEO, Addex Therapeutics

Walter Schmidt, CEO, AFFiRiS

Sjaak Deckers, CEO, Sapiens Steering Brain Stimulation

David Fineman, CEO, KineMed
 4:30 New Developments in Pain and Migraine
  Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatments for chronic, neuropathic pain, and migraine.

Session Chair: John Reppas, Neurotech Industry Organization, Life Science Angels

Kumar Bhargava, CEO, Sarentis Therapeutics

Stephen Collins, President & CEO, Neurotherapeutics Pharma

Ting Lu, President, COO & CFO, eNeura

Jon Snyder, CEO, Neuros Medical
Networking Reception
  Tuesday May 22, 2012
Continental Breakfast & Registration
 8:30 Partnering and Licensing in Neurotech Panel
  Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions?  With big pharma paying more attention to neurodiagnostics, what kinds of deals and partnerships can we expect in 2012?

Moderator: Eric Linsley, Managing Partner, Pappas Ventures

Richard Brudnick, Vice President Business Development, Biogen Idec

Jeffrey Erb,

Sr. Director of BD, Alliances and IP Management, Medtronic Neuromodulation

Jonathan Garen, Executive Director, Business Development, Forest Laboratories

David Schulz, Sr. Director, Business Development,

Networking and Refreshment Break
10:15 Frontiers in Neurotechnology
  In this session we will hear from companies on the cutting edge. Novel neurostimulation devices and drug platforms are being developed for new markets including sensory disorders, hypertension, obesity, sleep apnea, neuroimmunology and many others. New technology developed in other fields is yielding benefits in neurodiagnostics. Exciting new platforms leveraging cutting edge techniques are being used for drug discovery. Don't miss this preview of next generation products and companies.

Session Chair: Corey McCann, Principal, MPM Capital

Judith Kelleher-Andersson, CEO, NeuroNascent

Leon Ekchian, CEO, NeuroSigma

Jean-Pierre Rosat, CEO, Aleva Neurotherapeutics

Will Rosellini, CEO, MicroTransponder

William Tyler, Founder, NeuroTrek
11:30 Improving Signal Detection in CNS Trials
  Companies will discuss lessons learned and strategies for improving signal detection in clinical trials for drugs and devices including centralized ratings, adaptive trials design and the use of biomarkers. 

Session Chair: Michael Detke, Chief Medical Officer, MedAvante

David Reasner, VP, Data Science, Sunovion

Michael Pencina, Associate Professor, Biostatistics, Boston University, Director Statistical Consulting, Harvard Clinical Research Institute

Roy Perlis, Director, Center for Experimental Drugs and Diagnostics, Department of Psychiatry and Center for Human Genetic Research, MGH, Associate Professor, HMS

Joan Shen, MD, PhDSenior Medical Director, China Clinical Lead, PCBU, Pfizer Inc.
2:00 Next Generation Psychiatry
  Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market.  What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?

Session Chair: Kiran Reddy, Principal, Third Rock Ventures

Albert Robichaud, CSO, Sage Therapeutics

Derek Small, CEO, Naurex

Eric Meier, CEO, Cervel Neurotechnology

Gregory Bayer, CEO, Brain Resource
3:00 NIO Working Group
  An overview and participant discussion of current and future congressional, FDA, and CMS initiatives to advance neurotech.  All are welcome.

Zack Lynch, Executive Director, Neurotech Industry Organization

John Reppas, Director of Public Policy, Neurotech Industry Organization

Daniel Ritter, 
Partner, K&L Gates, NIO Public Policy Counsel

Suzan Onel, Partner, K&L Gates, NIO Regulatory Counsel

Refreshments and One -to- One Networking Time
 5:30 Conference Concludes


Contact Information